ABSTRACT
INTRODUCTION
glucagon-like peptide-1 (GLP-1) based therapies may reduce inflammation (11-13) and enhance 1 protein expression of SIRT1 (14) . Moreover, human studies showed that sitagliptin (15) and 2 exenatide (16), even at a single dose, exert a potent anti-inflammatory effect and many of these 3 effects were persistent over a period of 12 weeks, thus suggesting that the anti-inflammatory effects 4 of GLP-1 based therapies could contribute to reduce atherogenesis 5 Here, we evaluated the effect of incretin therapy of diabetic patients on SIRT6 expression in carotid 6 plaques and early outgrown circulating endothelial progenitor cells (EPCs). Furthermore, a set of 7 in-vitro experiments on EC and EPCs was designed to evaluate the effect of incretin on SIRT6 and 8 NF-ĸB during high-glucose treatment. and baseline evaluations were performed 7 days before surgery. Thereafter, the patients were asked 7 to perform self-monitoring blood glucose (fasting, post-breakfast, post-meal and post-dinner 8 glucose levels) until the day of surgery. Levels of fasting blood glucose were evaluated before 9 surgery. Fasting and post-prandial plasma glucose data were obtained from the average of each 10 assessment.
11
Atherectomy specimens. After surgery, the specimens were cut perpendicular to the long axis into 12 two halves. The first half was frozen in liquid nitrogen for the following ELISA analysis. A portion 13 of the other half specimen was immediately immersion-fixed in 10% buffered formalin. Sections 14 were serially cut at 5 µm, mounted on lysine-coated slides, and stained with hematoxylin and eosin 15 and with the trichrome method. Carotid artery specimens were analyzed by light microscopy. respectively; anti-matrix metalloproteinase-9 (MMP-9) (Santa Cruz), proteases involved in the 22 degradation of the collagen content in the plaque; and anti-tumor necrosis factor (TNF)-α (R&D).
23
Analysis of immunohistochemistry was performed with a personal computer-based quantitative 24-24 bit color image analysis system (IM500; Leica Microsystem AG).
Sirius red staining for collagen content. Sections were stained as previously described (19). After 1 dehydration, the sections were observed under polarized light after being placed on coverslips. The 2 sections were photographed with identical exposure settings for each section.
3
Biochemical assays. Plaques were lysed and centrifuged for 10 min at 10,000 g at 4°C. After 4 centrifugation, 20 µg of each sample were loaded, electrophoresed in polyacrylamide gel, and 5 electroblotted onto a nitrocellulose membrane. Each determination was repeated at least three times.
6
MMP-9, TNF-α, and nitrotyrosine levels were quantified in plaques using a specific ELISA kits 7 (from Santa Cruz, R&D Systems, and Imgenex). SIRT6 activity was measured using fluorimetric 8 SIRT6 assay kit (Abcam, Cambridge, UK). NF-ĸB binding to kB sites was assessed on nuclear 9 extracts from plaque specimens (19) by the Trans-AM NF-ĸB p65 transcription factor assay kit 10 (Active Motif Europe; Rixensart).
11
Isolation and culture of EPCs. Early outgrown EPCs were isolated from leukocyte-rich buffy coat 12 of human healthy volunteers and peripheral blood from diabetic (n=5 current incretin-users and n=5 13 never incretin-users) and non-diabetic (n=10) patients were isolated and characterized as previously 14 described (20, 21).
15
In vitro cell treatments. EC, human aortic endothelial cells (HAECs), were from Lonza (Cologne,
16
Walkersville, MD, USA). Cells were cultured with EGM-2MV BulletKit (Lonza) supplemented 17 with 5 % FBS, 0.6 % HEPES, maintained at 37 °C in a 5 % CO 2 humidified atmosphere, and used
18
in experiments between passage 4 and 7. EPCs (5 x 10 6 cells/ml medium) and EC (cultured at 70-Confocal laser-scanning microscopy. non-normally distributed data. When differences among the groups were found, Bonferroni 20 correction to make pairwise comparisons was used. P < 0.05 was considered statistically 21 significant. All calculations were performed using SPSS 12.
RESULTS

1
Demographic data for the study population are presented in Table 1 and supplementary Table. 2
Percentage of carotid diameter reduction, risk factors, and concomitant non-hypoglycemic therapy 3 did not differ among the groups ( Table 1 and supplementary Table) . In diabetic patients, mean, 4 fasting and post-prandial plasma glucose levels at baseline as well as during the week before the 5 surgery, HOMA-IR and HbA1c (A1C) levels did not differ among never incretin-users and current 6 incretin-users ( Table 1 and supplementary Table) . However, basal and post-prandial GLP-1 7 levels were higher in current incretin-users compared to never incretin-users (P<0.01) ( nitrotyrosine levels were found in diabetic than in non-diabetic plaques (P< 0.001). Among diabetic plaques, nitrotyrosine levels were significantly higher in never incretin-users than in current 1 incretin-users (P<0.01) ( Table 1 Factor, thus, suggesting that SIRT6 is expressed by EC (Fig. 4, plaques from non-diabetic and diabetic patients (current and never incretin-users) showed a similar 14 trend (Fig. 4, panel C) . Moreover, SIRT6 expression levels in plaques were inversely correlated 15 with GLP-1 levels (r=-0.58, P<0.001). NF-ĸB activation, as reflected by the selective analysis of the 16 activated form of both p50 and p65, was significantly higher higher in both current incretin-users 17 (P<0.01) and never incretin-users (P< 0.01) than in non-diabetic plaques. In plaques from diabetic 18 patients, NF-ĸB were significantly higher in never incretin-users than in current incretin-users
19
( Table 1) .
20
SIRT6 protein levels in EPCs from diabetic and non-diabetic patients.
21
It is already known from experimental and clinical studies that atherosclerosis is associated with Western blot analysis revealed that EPCs from diabetic never incretin-users had lower values of 1 SIRT6 protein arbitrary units (AU) and that diabetic patients current incretin-users had levels of 2 SIRT6 higher than those observed in EPCs from never incretin-users (P<0.05) (Fig. 5) .
3
In vitro effect of high-glucose and GLP-1 receptor agonist on SIRT6 and NF-ĸB expression in 4 EPCs and EC.
5
In light of the observational data that diabetic patients never incretin-users showed decreased levels 6 of SIRT6 protein in either atherosclerotic plaque sections and EPCs, and that incretin therapies 7 seems to prevent SIRT6 downregulation (Fig. 3, 4 , 5), we next evaluated whether the detrimental 8 effect high-glucose concentration on EPCs and EC (20) is exerted via SIRT6/NF-ĸB pathway.
9
Western blot and confocal-laser scanning microscopy analysis revealed that short-term exposure of 10 early EPCs (Fig. 6) and EC ( Fig. 7) to high-glucose concentration induces downregulation of 11 SIRT6 protein (P<0.01) with a concomitant upregulation of NF-ĸB protein expression (P<0.01)
12
( Fig. 6, 7) .
13
The dose-dependent response (from 1 to 1000 nM) effect of GLP-1 on SIRT6 activity during short- both SIRT6 and NF-ĸB protein levels (P<0.05) (Fig. 6, panel A, B, C) .
21
Similar results were obtained when EC were subjected to high-glucose treatment in the presence or 22 absence of GLP-1 (100 nM) (Fig. 7, panel A, B, C) . Indeed, the presence of GLP-1 during high- and the downregulation of SIRT6 expression.
11
A previous study in mice has suggested a role for SIRT6 in inflammation (9), as well as a 12 recent experimental study on endothelial cells which showed that the loss of SIRT6 is associated 13 with up-regulation of genes involved in inflammation, vascular remodelling, and angiogenesis (4). the possibility of a novel pathway to be unveiled through which the incretin system impairment, by 6 reducing SIRT6 expression, could mediate inflammatory activity in diabetic atherosclerotic plaques.
7
Thus, modulation of SIRT6 through incretin system could be beneficial for many inflammatory inflammation, metabolic diseases, and atherosclerosis.
5
As whole, our data might have strong clinical implications because in a large series of 6 carotid endarterectomy specimens it has been shown that plaque inflammation is one of the major 7 determinants of ischemic events in patients affected by carotid atherosclerotic disease (28). Furthermore, it should be noted that in both studies patients were randomized to DPP-4 inhibitors or 11 placebo on top of standard therapy, usually metformin (alone or in combination with other agents),
12
which was taken by about two-thirds of the patients. Moreover, almost half of the patients were
13
taking sulfonylureas, that may be associated with increased mortality (36). Finally, both studies
14
were conducted in patients with cardiovascular disease and, therefore, the assessment of prevention
15
of events with incretins may not be accurate. However, the effects of incretin-mimetic drugs on 16 cardiovascular events and mortality cannot be considered established unless it is evaluated in long-17 term cardiovascular outcomes trials in patients without cardiovascular diseases.
18
In conclusion, we demonstrated that GLP-1 reduced plaque macrophage infiltration and MMP-9 weekly) on SIRT 6 expression need to be determined. 9 (MMP-9) (X400), sirius red staining for collagen content (X400), nitrotyrosine (X400) and sirtuin 11 6 (SIRT6) (X400) in control, current incretin-user, and never incretin-user asymptomatic plaques. 
